Finerenon

Die diabetische Nephropathie, eine Manifestation der diabetischen Mikroangiopathie, ist weiterhin die häufigste Ursache der terminalen dialysepflichtigen Niereninsuffizienz in den Industrienationen. Dies zeigen u. a. aktuelle Daten des Registers der „European Renal Association – European Dialysis and Transplant Association“ (ERA-EDTA) [1]. Die Pathophysiologie der diabetischen Nephropathie ist komplex. Wesentliche Progressionsfaktoren sind Hyperfiltration und Inflammation neben mangelhafter Kontrolle des Glukosestoffwechsels ([Abb. 2]).

Publication History

Article published online:
23 April 2021

• Literatur

• 1 Kramer A, Boenink R, Noordzij M. et al The ERA-EDTA Registry Annual Report 2017: a summary. Clin Kidney J 2020; 13: 693-709 DOI: 10.1093/ckj/sfaa048.
• 2 Barnett A, Bain S, Bouter P. et al Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351: 1952-1961 DOI: 10.1056/NEJMoa042274.
• 3 de Galan B, Perkovic V, Ninomiya T. et al Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20: 883-892 DOI: 10.1681/ASN.2008070667.
• 4 ADVANCE Collaborative Group Patel A, MacMahon S. et al Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572 DOI: 10.1056/NEJMoa0802987.
• 5 Wanner C, Inzucchi SE, Lachin JM. et al Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323-334 DOI: 10.1056/NEJMoa1515920.
• 6 Zinman B, Wanner C, Lachin JM. et al Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128 DOI: 10.1056/NEJMoa1504720.
• 7 Marso SP, Daniels GH, Brown-Frandsen K. et al Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375: 311-322 DOI: 10.1056/NEJMoa1603827.
• 8 Ito M, Tanaka T. The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors. Intern Med 2018; 57: 2105-2114 DOI: 10.2169/internalmedicine.9842-17.
• 9 de Zeeuw D, Akizawa T, Audhya P. et al Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369: 2492-2503 DOI: 10.1056/NEJMoa1306033.
• 10 Schjoedt KJ, Rossing K, Juhl TR. et al Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542 DOI: 10.1038/sj.ki.5001580.
• 11 Schjoedt KJ, Rossing K, Juhl TR. et al Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836 DOI: 10.1111/j.1523-1755.2005.00756.x.
• 12 Zuo C, Xu G. Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta-analysis. Int J Clin Pract. 2019 Aug 29 e13413 DOI: 10.1111/ijcp.13413
• 13 Dutzmann J, Musmann R-J, Haertlé M. et al The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury. PLoS One 2017; 12: e0184888 DOI: 10.1371/journal.pone.0184888.
• 14 Rico-Mesa JS, White A, Ahmadian-Tehrani A, Anderson AS. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone. Curr Cardiol Rep 2020; 22: 140 DOI: 10.1007/s11886-020-01399-7.
• 15 Bakris GL, Agarwal R, Anker SD. et al Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Am J Nephrol 2019; 50: 333-344 DOI: 10.1159/000503713.
• 16 Bakris GL, Agarwal R, Anker SD. et al Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383: 2219-2229 DOI: 10.1056/NEJMoa2025845.
• 17 Perkovic V, Jardine MJ, Neal B. et al Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380: 2295-2306 DOI: 10.1056/NEJMoa1811744.